Amikacin Inhibits miR-497 Maturation and Exerts Post-ischemic Neuroprotection

S. Sinoy, S. M. Fayaz, K. D. Charles, V. K. Suvanish, Josef P. Kapfhammer, G. K. Rajanikant

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

MicroRNAs (miRNAs) are a group of small non-coding RNAs that regulate numerous signaling pathways involved in cerebral ischemia reperfusion injury. Recent finding demonstrated that miR-497 promotes ischemic neuronal death by negatively regulating anti-apoptotic proteins and therefore serves as a promising therapeutic target for cerebral ischemic injury. In this study, we present a systematic computational approach that includes 3D modeling, docking-based virtual screening, and molecular dynamics simulation to identify small-molecule inhibitors of pre-miR-497 maturation. The top hit, aminoglycosidic antibiotic, amikacin, formed a stable complex with pre-miR-497. Later, the protective efficacy of amikacin was evaluated against oxygen-glucose deprivation (OGD) and reoxygenation-induced neuronal cell death in SH-SY5Y cells and mouse organotypic hippocampal slice cultures. To confirm the inhibitory potential of amikacin on miR-497 maturation, quantitative real-time PCR was performed to check the expression of bcl-2, one of the primary anti-apoptotic targets of miR-497. Additionally, the expression level of mature miR-497 was quantified using TaqMan® MiRNA Assay Kit. Amikacin treatment effectively reduced OGD-induced cell death compared to control groups both in vitro and organotypic hippocampal slice cultures. Further, amikacin effectively increased the expression of bcl-2 in SH-SY5Y cells subjected to OGD. Interestingly, SH-SY5Y cells treated with amikacin displayed decreased expression of miR-497, probably due to inhibition of pre-miRic form. Our study provides strong evidence that amikacin inhibits miR-497 maturation and promotes ischemic neuronal survival by upregulating anti-apoptotic protein, bcl-2. Future studies directed at evaluating the neuroprotective efficacy and mechanism of amikacin animal models may lead to new therapeutic opportunities for preventing neuronal death after stroke.

Original languageEnglish
Pages (from-to)3683-3694
Number of pages12
JournalMolecular Neurobiology
Volume54
Issue number5
DOIs
Publication statusPublished - 01-07-2017

Fingerprint

Amikacin
Apoptosis Regulatory Proteins
Oxygen
Glucose
Cell Death
Small Untranslated RNA
Neuroprotection
Molecular Dynamics Simulation
Reperfusion Injury
Brain Ischemia
MicroRNAs
Real-Time Polymerase Chain Reaction
Animal Models
Stroke
Anti-Bacterial Agents
Control Groups
Wounds and Injuries
Therapeutics

All Science Journal Classification (ASJC) codes

  • Cellular and Molecular Neuroscience

Cite this

Sinoy, S., Fayaz, S. M., Charles, K. D., Suvanish, V. K., Kapfhammer, J. P., & Rajanikant, G. K. (2017). Amikacin Inhibits miR-497 Maturation and Exerts Post-ischemic Neuroprotection. Molecular Neurobiology, 54(5), 3683-3694. https://doi.org/10.1007/s12035-016-9940-0
Sinoy, S. ; Fayaz, S. M. ; Charles, K. D. ; Suvanish, V. K. ; Kapfhammer, Josef P. ; Rajanikant, G. K. / Amikacin Inhibits miR-497 Maturation and Exerts Post-ischemic Neuroprotection. In: Molecular Neurobiology. 2017 ; Vol. 54, No. 5. pp. 3683-3694.
@article{8c5eb606ce8348beb3efbab481ea7df5,
title = "Amikacin Inhibits miR-497 Maturation and Exerts Post-ischemic Neuroprotection",
abstract = "MicroRNAs (miRNAs) are a group of small non-coding RNAs that regulate numerous signaling pathways involved in cerebral ischemia reperfusion injury. Recent finding demonstrated that miR-497 promotes ischemic neuronal death by negatively regulating anti-apoptotic proteins and therefore serves as a promising therapeutic target for cerebral ischemic injury. In this study, we present a systematic computational approach that includes 3D modeling, docking-based virtual screening, and molecular dynamics simulation to identify small-molecule inhibitors of pre-miR-497 maturation. The top hit, aminoglycosidic antibiotic, amikacin, formed a stable complex with pre-miR-497. Later, the protective efficacy of amikacin was evaluated against oxygen-glucose deprivation (OGD) and reoxygenation-induced neuronal cell death in SH-SY5Y cells and mouse organotypic hippocampal slice cultures. To confirm the inhibitory potential of amikacin on miR-497 maturation, quantitative real-time PCR was performed to check the expression of bcl-2, one of the primary anti-apoptotic targets of miR-497. Additionally, the expression level of mature miR-497 was quantified using TaqMan{\circledR} MiRNA Assay Kit. Amikacin treatment effectively reduced OGD-induced cell death compared to control groups both in vitro and organotypic hippocampal slice cultures. Further, amikacin effectively increased the expression of bcl-2 in SH-SY5Y cells subjected to OGD. Interestingly, SH-SY5Y cells treated with amikacin displayed decreased expression of miR-497, probably due to inhibition of pre-miRic form. Our study provides strong evidence that amikacin inhibits miR-497 maturation and promotes ischemic neuronal survival by upregulating anti-apoptotic protein, bcl-2. Future studies directed at evaluating the neuroprotective efficacy and mechanism of amikacin animal models may lead to new therapeutic opportunities for preventing neuronal death after stroke.",
author = "S. Sinoy and Fayaz, {S. M.} and Charles, {K. D.} and Suvanish, {V. K.} and Kapfhammer, {Josef P.} and Rajanikant, {G. K.}",
year = "2017",
month = "7",
day = "1",
doi = "10.1007/s12035-016-9940-0",
language = "English",
volume = "54",
pages = "3683--3694",
journal = "Molecular Neurobiology",
issn = "0893-7648",
publisher = "Humana Press",
number = "5",

}

Sinoy, S, Fayaz, SM, Charles, KD, Suvanish, VK, Kapfhammer, JP & Rajanikant, GK 2017, 'Amikacin Inhibits miR-497 Maturation and Exerts Post-ischemic Neuroprotection', Molecular Neurobiology, vol. 54, no. 5, pp. 3683-3694. https://doi.org/10.1007/s12035-016-9940-0

Amikacin Inhibits miR-497 Maturation and Exerts Post-ischemic Neuroprotection. / Sinoy, S.; Fayaz, S. M.; Charles, K. D.; Suvanish, V. K.; Kapfhammer, Josef P.; Rajanikant, G. K.

In: Molecular Neurobiology, Vol. 54, No. 5, 01.07.2017, p. 3683-3694.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Amikacin Inhibits miR-497 Maturation and Exerts Post-ischemic Neuroprotection

AU - Sinoy, S.

AU - Fayaz, S. M.

AU - Charles, K. D.

AU - Suvanish, V. K.

AU - Kapfhammer, Josef P.

AU - Rajanikant, G. K.

PY - 2017/7/1

Y1 - 2017/7/1

N2 - MicroRNAs (miRNAs) are a group of small non-coding RNAs that regulate numerous signaling pathways involved in cerebral ischemia reperfusion injury. Recent finding demonstrated that miR-497 promotes ischemic neuronal death by negatively regulating anti-apoptotic proteins and therefore serves as a promising therapeutic target for cerebral ischemic injury. In this study, we present a systematic computational approach that includes 3D modeling, docking-based virtual screening, and molecular dynamics simulation to identify small-molecule inhibitors of pre-miR-497 maturation. The top hit, aminoglycosidic antibiotic, amikacin, formed a stable complex with pre-miR-497. Later, the protective efficacy of amikacin was evaluated against oxygen-glucose deprivation (OGD) and reoxygenation-induced neuronal cell death in SH-SY5Y cells and mouse organotypic hippocampal slice cultures. To confirm the inhibitory potential of amikacin on miR-497 maturation, quantitative real-time PCR was performed to check the expression of bcl-2, one of the primary anti-apoptotic targets of miR-497. Additionally, the expression level of mature miR-497 was quantified using TaqMan® MiRNA Assay Kit. Amikacin treatment effectively reduced OGD-induced cell death compared to control groups both in vitro and organotypic hippocampal slice cultures. Further, amikacin effectively increased the expression of bcl-2 in SH-SY5Y cells subjected to OGD. Interestingly, SH-SY5Y cells treated with amikacin displayed decreased expression of miR-497, probably due to inhibition of pre-miRic form. Our study provides strong evidence that amikacin inhibits miR-497 maturation and promotes ischemic neuronal survival by upregulating anti-apoptotic protein, bcl-2. Future studies directed at evaluating the neuroprotective efficacy and mechanism of amikacin animal models may lead to new therapeutic opportunities for preventing neuronal death after stroke.

AB - MicroRNAs (miRNAs) are a group of small non-coding RNAs that regulate numerous signaling pathways involved in cerebral ischemia reperfusion injury. Recent finding demonstrated that miR-497 promotes ischemic neuronal death by negatively regulating anti-apoptotic proteins and therefore serves as a promising therapeutic target for cerebral ischemic injury. In this study, we present a systematic computational approach that includes 3D modeling, docking-based virtual screening, and molecular dynamics simulation to identify small-molecule inhibitors of pre-miR-497 maturation. The top hit, aminoglycosidic antibiotic, amikacin, formed a stable complex with pre-miR-497. Later, the protective efficacy of amikacin was evaluated against oxygen-glucose deprivation (OGD) and reoxygenation-induced neuronal cell death in SH-SY5Y cells and mouse organotypic hippocampal slice cultures. To confirm the inhibitory potential of amikacin on miR-497 maturation, quantitative real-time PCR was performed to check the expression of bcl-2, one of the primary anti-apoptotic targets of miR-497. Additionally, the expression level of mature miR-497 was quantified using TaqMan® MiRNA Assay Kit. Amikacin treatment effectively reduced OGD-induced cell death compared to control groups both in vitro and organotypic hippocampal slice cultures. Further, amikacin effectively increased the expression of bcl-2 in SH-SY5Y cells subjected to OGD. Interestingly, SH-SY5Y cells treated with amikacin displayed decreased expression of miR-497, probably due to inhibition of pre-miRic form. Our study provides strong evidence that amikacin inhibits miR-497 maturation and promotes ischemic neuronal survival by upregulating anti-apoptotic protein, bcl-2. Future studies directed at evaluating the neuroprotective efficacy and mechanism of amikacin animal models may lead to new therapeutic opportunities for preventing neuronal death after stroke.

UR - http://www.scopus.com/inward/record.url?scp=84969791900&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84969791900&partnerID=8YFLogxK

U2 - 10.1007/s12035-016-9940-0

DO - 10.1007/s12035-016-9940-0

M3 - Article

VL - 54

SP - 3683

EP - 3694

JO - Molecular Neurobiology

JF - Molecular Neurobiology

SN - 0893-7648

IS - 5

ER -